Pernelle Lavaud

1.4k total citations
71 papers, 551 citations indexed

About

Pernelle Lavaud is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Pernelle Lavaud has authored 71 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in Pernelle Lavaud's work include Cancer Immunotherapy and Biomarkers (26 papers), Lung Cancer Treatments and Mutations (23 papers) and Lung Cancer Research Studies (16 papers). Pernelle Lavaud is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Lung Cancer Treatments and Mutations (23 papers) and Lung Cancer Research Studies (16 papers). Pernelle Lavaud collaborates with scholars based in France, Spain and Italy. Pernelle Lavaud's co-authors include Fabrice André, Yohann Loriot, Benjamin Besse, David Planchard, Charles Naltet, Laura Mezquita, Christophe Massard, Karim Fizazi, Giulia Baciarello and Anas Gazzah and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Pernelle Lavaud

66 papers receiving 546 citations

Peers

Countries citing papers authored by Pernelle Lavaud

Since Specialization

Citations

This map shows the geographic impact of Pernelle Lavaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pernelle Lavaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pernelle Lavaud more than expected).

Fields of papers citing papers by Pernelle Lavaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pernelle Lavaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pernelle Lavaud. The network helps show where Pernelle Lavaud may publish in the future.

Co-authorship network of co-authors of Pernelle Lavaud

This figure shows the co-authorship network connecting the top 25 collaborators of Pernelle Lavaud. A scholar is included among the top collaborators of Pernelle Lavaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pernelle Lavaud. Pernelle Lavaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography	European Journal of Cancer Prevention	Henri Leleu, Julia Bonastre et al.	0
2	Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study	ESMO Open	Florian Guisier, Pernelle Lavaud et al.	2
3	Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies	Cancers	Pernelle Lavaud, Lodovica Zullo et al.	9
4	Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms	JTO Clinical and Research Reports	Claudia Parisi, Damien Vasseur et al.	0
5	Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer	European Journal of Cancer	Marco Tagliamento, Édouard Auclin et al.	25
6	Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma	Cancers	Édouard Auclin, Anna Patrikidou et al.	10
7	1334P Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency	Annals of Oncology	Maria‐Rosa Ghigna, J. Remon Masip et al.	2
8	Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer	Clinical Lung Cancer	Mariona Riudavets, Damien Vasseur et al.	1
9	478P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study	Annals of Oncology	Alice Hervieu, J. Guigay et al.	4
10	Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors	npj Precision Oncology	Marianne Oulhen, Patrycja Pawlikowska et al.	17
11	Impact de l’utilisation de la corticothérapie systémique sur l’efficacité des inhibiteurs de points de contrôle immunitaire	Bulletin du Cancer	Maria Kfoury, Pernelle Lavaud et al.	1
12	1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC)	Annals of Oncology	Mihaela Aldea, Claudia Parisi et al.	3
13	Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study	Frontiers in Oncology	Nicolas Epaillard, Yohann Loriot et al.	9
14	Nouvelles AMMs : ipilimumab-nivolumab en association à la chimiothérapie en première ligne dans le cancer bronchique non à petites cellules métastatiques	Bulletin du Cancer	Pernelle Lavaud et al.	1
15	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome	European Journal of Cancer	Émeline Colomba, Grégoire Marret et al.	11
16	1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)	Annals of Oncology	Roberto Ferrara, Francesco Facchinetti et al.	7
17	1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial	Annals of Oncology	Benjamin Besse, Julien Adam et al.	74
18	638P Meningeal metastases (MM) in patients with metastatic castration resistant prostate cancer (mCRPC)	Annals of Oncology	Mihaela Aldea, Luigi Cerbone et al.	3
19	P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients	Journal of Thoracic Oncology	Laura Mezquita, Santiago Ponce Aix et al.	1
20	P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy	Journal of Thoracic Oncology	Angela Botticella, Toni Ibrahim et al.	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact